Fineline Cube

Follow:
14415 Articles
CTTQ Deepens Partnership with Shionogi to Accelerate Naldemedine Launch in China
CompanyDeals

CTTQ Deepens Partnership with Shionogi to Accelerate Naldemedine Launch in China

FDA CDER Director George Tidmarsh Placed on Leave Amid Probe Over Drug‑Approval Program Concerns
Policy / Regulatory

FDA CDER Director George Tidmarsh Placed on Leave Amid Probe Over Drug‑Approval Program Concerns

Lepu’s Minwei Licenses MWN105 Injection to Denmark’s Sidera Bio, Up to $1.01 B in Milestones
CompanyDeals

Lepu’s Minwei Licenses MWN105 Injection to Denmark’s Sidera Bio, Up to $1.01 B in Milestones

Transcenta Holding Announces Positive Phase III Results for Inhibrx’s Ozekibart in Advanced Chondrosarcoma
CompanyDrug

Transcenta Holding Announces Positive Phase III Results for Inhibrx’s Ozekibart in Advanced Chondrosarcoma

Boehringer Ingelheim Licenses Pre‑Clinical Small‑Molecule Program from Kyowa Kirin for Autoimmune Therapy
CompanyDeals

Boehringer Ingelheim Licenses Pre‑Clinical Small‑Molecule Program from Kyowa Kirin for Autoimmune Therapy

Chengdu Maxvax Secures Series D Financing at Over RMB 400 Million to Accelerate Shingles and RSV Vaccine Development
CompanyDeals

Chengdu Maxvax Secures Series D Financing at Over RMB 400 Million to Accelerate Shingles and RSV Vaccine Development

BMS Reports Q3 2025 Results: 2 % Global Revenue Growth
Company

BMS Reports Q3 2025 Results: 2% Global Revenue Growth

Gilead Sciences Reports 3% YoY Q3 2025 Revenue Growth, HIV Sales Up 4%
Company

Gilead Sciences Reports 3% YoY Q3 2025 Revenue Growth, HIV Sales Up 4%

MSD Reports 3% YoY Q3 2025 Sales Growth, Keytruda Drives 8% Lift, Verona Acquisition Strengthens Cardio‑Pulmonary Portfolio
Company

MSD Reports 3% YoY Q3 2025 Sales Growth, Keytruda Drives 8% Lift, Verona Acquisition Strengthens Cardio‑Pulmonary Portfolio

Eli Lilly Reports 54% YoY Revenue Surge in Q3 2025, Raises Full‑Year Guidance to $63 B
Company

Eli Lilly Reports 54% YoY Revenue Surge in Q3 2025, Raises Full‑Year Guidance to $63 B

Jebel Pharma Reports Positive Phase III Results for JJH201501 Antidepressant
CompanyDrug

Jebel Pharma Reports Positive Phase III Results for JJH201501 Antidepressant

Shanghai Bio‑Heart’s Iberis RDN System Gains UK MHRA Approval, Expands Global Commercial Reach
CompanyMedical Device

Shanghai Bio‑Heart’s Iberis RDN System Gains UK MHRA Approval, Expands Global Commercial Reach